NCT06060782View on ClinicalTrials.gov

Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Burkitt LymphomaLymphoblastic Lymphoma, AdultAcute Lymphoblastic Leukemia, Adult
Interventions
DRUG

Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen

"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"

Trial Locations (1)

519000

RECRUITING

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

All Listed Sponsors
lead

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER